We leveraged Olink CSF and plasma data from control (n=90) and Parkinson’s disease (PD, n=118) subjects in the Accelerating Medicines Partnership for Parkinson’s Disease (AMP-PD) consortium to test the specificity of SMOC1 for AD (Fig. 1B). This evidence concerns the gene SMOC1 and Alzheimer disease.